ImmuneOnco started Phase Ib/II Clinical Study of IMM01: An IMM01 combined with azacitidine clinical trial completed the first patient enrollment and dosing

On January 5, 2022, Shanghai, China, ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd.， (hereinafter referred to as "ImmuneOnco") announced that SIRPaFc recombinant protein targeting human CD47 ，IMM01， combined with azacitidine (AZA) in the treatment of re......

2022-01-05

ImmuneOnco grandly held the groundbreaking ceremony of its headquarter and biopharmaceutical manufacturing base

The first sod was turned in the morning on the first working day of the new year (January 4, 2022). The groundbreaking ceremony of "ImmuneOnco Headquarter and Biopharmaceutical Manufacturing Base" was grandly held in the campus of ‘Innovative Medicine Bas......

2022-01-04

ImmuneOnco announced the completion of nearly 100 million U.S. dollars in C round of financing

On December 31, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced completion of a C-round financing of nearly $100 million USD. The financing was funded by new investors such as Sunshine life Insu......

2021-12-31

ImmuneOnco is enlisted in‘’2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China‘’

Dec. 21, 2021, Shanghai, China. The list of ‘2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China’ was made public today. ImmuneOnco was successfully selected for the name of the list and it is highly recognize......

2021-12-21

NMPA accepted the clinical trial application of IMM01 combined with PD-1 antibody for the treatment of relapsed and refractory malignant tumors

On December 13, 2021, I ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the application for the clinical trial, the SIRPαFc fusion protein (IMM01) targeting human CD47, combined with PD-1 antibody to treat relapsed and refractory ......

2021-12-14